David Bharucha
Known title: Chief Medical OfficerCIK: 0001910985
David Bharucha's purchase track record
David Bharucha has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/1/2022 | MIST | $47K | -33.3% | -23.9% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MIST | ▼ Sell | Open Market | 12,245 | $24K | 1/26/2026 | View on chart |
| MIST | ▲ Buy | Option Exercise | 20,100 | — | 1/26/2026 | View on chart |
| MIST | ▼ Sell | Open Market | 58,007 | $135K | 12/15/2025 | View on chart |
| MIST | ▲ Buy | Grant | 100,000 | — | 12/12/2025 | View on chart |
| MIST | ▲ Buy | Grant | 53,333 | — | 7/11/2025 | View on chart |
| MIST | ▲ Buy | Open Market | 7,000 | $33K | 12/5/2022 | View on chart |
| MIST | ▲ Buy | Open Market | 3,000 | $15K | 12/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial
Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.